Wall Street Zen Downgrades Jupiter Neurosciences (NASDAQ:JUNS) to Strong Sell

Jupiter Neurosciences (NASDAQ:JUNS) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Jupiter Neurosciences presently has a consensus rating of “Sell”.

Jupiter Neurosciences Price Performance

Shares of Jupiter Neurosciences stock opened at $5.10 on Friday. The firm has a market cap of $2.45 million, a P/E ratio of -0.25 and a beta of 1.99. Jupiter Neurosciences has a fifty-two week low of $4.76 and a fifty-two week high of $137.96. The business has a 50-day moving average price of $14.34 and a 200 day moving average price of $27.32.

Jupiter Neurosciences (NASDAQ:JUNS) last released its earnings results on Thursday, May 14th. The company reported ($4.50) EPS for the quarter, missing analysts’ consensus estimates of ($3.75) by ($0.75). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.23 million.

Hedge Funds Weigh In On Jupiter Neurosciences

Large investors have recently bought and sold shares of the business. Allen Capital Group LLC acquired a new position in Jupiter Neurosciences in the fourth quarter valued at approximately $31,000. Geode Capital Management LLC raised its position in shares of Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the period. Yorkville Advisors Global LP acquired a new stake in shares of Jupiter Neurosciences during the 4th quarter worth approximately $135,000. Finally, Vestor Capital LLC lifted its holdings in shares of Jupiter Neurosciences by 144,607.2% in the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares during the last quarter.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.